MAP2K7 and colorectal carcinoma: In conclusion, our data illustrate that the RTKs-GRB7-PLK1 signaling pathway plays a pivotal role in resistance to MEKis and a combinational inhibition of this axis and MEK provides a promising strategy to cure CRC patients with KRAS mutation (Fig. 8).